Table 2.
Univariate and Multivariate Analyses of Predictors of Death During Tuberculosis Treatment in TB/HIV Coinfected Patients in North Carolina, 1993–2003 (n = 307)
| Covariate | Univariate RR (95%CI) | Multivariate RR (95% CI) |
|---|---|---|
| Age | ||
| <45 | 1.00 (reference) | 1.00 (reference) |
| ≥45 | 1.85 (0.91, 3.76) | 2.18 (1.11, 4.29) |
| Race/ethnicity | ||
| White | 1.00 (reference) | |
| Hispanic | 0.56 (0.14, 2.28) | |
| Black | 0.55 (0.20, 1.48) | |
| Gender | ||
| Male | 1.00 (reference) | |
| Female | 1.35 (0.60–3.03) | |
| Site of disease | ||
| Pulmonary | 1.00 (reference) | |
| Extrapulmonary | 0.75 (0.23, 2.44) | |
| Pulmonary and extrapulmonary | 1.86 (0.79, 4.36) | |
| CD4 count (per 100 cells/mm3) | 0.55 (0.36, 0.86) | 0.53 (0.34, 0.81) |
| HAART use during TB treatment | ||
| No | 1.00 (reference) | 1.00 (reference) |
| Yes | 0.37 (0.13, 1.04) | 0.37 (0.13, 1.02) |
Only patients who survived long enough to receive at least one dose of TB treatment with available CD4 counts were included in this analysis. Patients of Asian and Native American races were also excluded due to low numbers (n = 3).
RR, relative risk; CI, confidence interval; HAART, highly active antiretroviral therapy.